About the Company: Global Point-of-Care Molecular Diagnostics Innovator
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary ‘Truenat’ platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.
The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent professionals.
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
The company’s promoters are Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Sriram Natarajan.
Financial Trends & Performance
Molbio Diagnostics Ltd.’s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Assets | ₹2,148.42 Cr | ₹1,461.56 Cr | ₹1,221.06 Cr |
| Total Income | ₹1,455.17 Cr | ₹1,027.94 Cr | ₹840.66 Cr |
| Profit After Tax (PAT) | ₹164.14 Cr | ₹138.58 Cr | ₹83.54 Cr |
| EBITDA | ₹328.24 Cr | ₹256.64 Cr | ₹185.09 Cr |
| Net Worth | ₹1,144.68 Cr | ₹952.95 Cr | ₹807.94 Cr |
| Reserves and Surplus | ₹1,148.84 Cr | ₹990.84 Cr | ₹845.48 Cr |
| Total Borrowings | ₹412.64 Cr | ₹123.16 Cr | ₹174.58 Cr |
All figures in ₹ Crore | Source: Chittorgarh / DRHP (Restated)
Key Performance Indicators & Valuation (FY2026)
Competitive Strengths
- WHO-Endorsed Technology: Proprietary Truenat platform featuring WHO-backed point-of-care molecular diagnostic solutions for TB and other infectious diseases.
- Extensive Patent Footprint: Robust in-house research and development infrastructure supported by an expanding international patent portfolio.
- Razor & Blade Business Model: Highly scalable revenue model driven by recurring sales of disease-specific diagnostic test kits.
- Global Reach: Commercial presence across 90+ countries with established government partnerships and healthcare institutional ties.
Issue Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
IPO Structure & Use of Proceeds
The ₹939.70 Cr issue comprises a Fresh Issue of ₹200.00 Cr (24,80,246 shares) and an Offer for Sale of ₹739.70 Cr (91,66,000 shares) by selling shareholders. The net fresh proceeds are proposed to be utilized as follows:
- Funding capital expenditure towards setting up infrastructure for R&D facility, Center of Excellence, and connected office space ₹125.12 Cr
- Funding capital expenditure towards purchase of plant, machinery, and equipment for Goa Unit I, Goa Unit II, and Visakhapatnam Unit ₹80.81 Cr
- General Corporate Purposes Balance
Bidding opens on August 10, 2026 and closes on August 12, 2026. Minimum retail application lot size is fixed at 18 shares (₹14,526 based on the upper price band).
Molbio Diagnostics Limited stands as a premier medical technology company, pioneering point-of-care molecular testing with its globally recognized Truenat platform. The business model combines high-margin, recurring diagnostic kit sales with expanding international adoption.
Financial growth remains strong, with total income surging 42% in FY26 to ₹1,455.17 Cr and PAT reaching ₹164.14 Cr. Allocating fresh capital toward expanding R&D infrastructure, setting up a Center of Excellence, and boosting production capacity in Goa and Visakhapatnam will solidify its long-term market leadership. Investors interested in innovative healthcare technology and point-of-care diagnostics may track this offering closely.
